These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 9816137

  • 1. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
    Bonetti A, Apostoli P, Zaninelli M, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R.
    Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
    [Abstract] [Full Text] [Related]

  • 2. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, Pearson AD, Boddy AV, Newell DR, Tilby MJ.
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [Abstract] [Full Text] [Related]

  • 3. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
    Fichtinger-Schepman AM, van der Velde-Visser SD, van Dijk-Knijnenburg HC, van Oosterom AT, Baan RA, Berends F.
    Cancer Res; 1990 Dec 15; 50(24):7887-94. PubMed ID: 2253228
    [Abstract] [Full Text] [Related]

  • 4. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
    Fisch MJ, Howard KL, Einhorn LH, Sledge GW.
    Clin Cancer Res; 1996 Jun 15; 2(6):1063-6. PubMed ID: 9816268
    [Abstract] [Full Text] [Related]

  • 5. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
    Tonda ME, Murry DJ, Rodman JH.
    Pharmacotherapy; 1996 Jun 15; 16(4):631-7. PubMed ID: 8840369
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.
    Cancer Chemother Pharmacol; 2002 Mar 15; 49(3):201-10. PubMed ID: 11935212
    [Abstract] [Full Text] [Related]

  • 7. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF, Le Pla RC, Jones GD, Thomas AL, Farmer PB.
    Chem Res Toxicol; 2010 Aug 16; 23(8):1313-21. PubMed ID: 20666396
    [Abstract] [Full Text] [Related]

  • 8. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
    Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S.
    Cancer Res; 1992 Jan 01; 52(1):149-53. PubMed ID: 1727376
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Reed E, Ostchega Y, Steinberg SM, Yuspa SH, Young RC, Ozols RF, Poirier MC.
    Cancer Res; 1990 Apr 15; 50(8):2256-60. PubMed ID: 2180564
    [Abstract] [Full Text] [Related]

  • 10. Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.
    Jarvis IW, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ.
    Biochem Pharmacol; 2012 Jan 01; 83(1):69-77. PubMed ID: 22015635
    [Abstract] [Full Text] [Related]

  • 11. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
    Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM.
    Cancer Res; 1993 Aug 15; 53(16):3694-9. PubMed ID: 8339278
    [Abstract] [Full Text] [Related]

  • 12. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
    Fichtinger-Schepman AM, Vendrik CP, van Dijk-Knijnenburg WC, de Jong WH, van der Minnen AC, Claessen AM, van der Velde-Visser SD, de Groot G, Wubs KL, Steerenberg PA.
    Cancer Res; 1989 Jun 01; 49(11):2862-7. PubMed ID: 2720647
    [Abstract] [Full Text] [Related]

  • 13. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 14. Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.
    Blommaert FA, Michael C, Terheggen PM, Muggia FM, Kortes V, Schornagel JH, Hart AA, den Engelse L.
    Cancer Res; 1993 Dec 01; 53(23):5669-75. PubMed ID: 8242622
    [Abstract] [Full Text] [Related]

  • 15. Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.
    Tilby MJ, Johnson C, Knox RJ, Cordell J, Roberts JJ, Dean CJ.
    Cancer Res; 1991 Jan 01; 51(1):123-9. PubMed ID: 1703029
    [Abstract] [Full Text] [Related]

  • 16. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
    Poirier MC, Egorin MJ, Fichtinger-Schepman AM, Yuspa SH, Reed E.
    IARC Sci Publ; 1988 Jan 01; (89):313-20. PubMed ID: 3058599
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):367-74. PubMed ID: 11976830
    [Abstract] [Full Text] [Related]

  • 18. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B, Tilby MJ, English MW, Price L, Pearson AD, Boddy AV, Newell DR.
    Br J Cancer; 1997 May 01; 76(11):1466-73. PubMed ID: 9400943
    [Abstract] [Full Text] [Related]

  • 19. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
    Gupta-Burt S, Shamkhani H, Reed E, Tarone RE, Allegra CJ, Pai LH, Poirier MC.
    Cancer Epidemiol Biomarkers Prev; 1993 May 01; 2(3):229-34. PubMed ID: 8318875
    [Abstract] [Full Text] [Related]

  • 20. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
    Parker RJ, Gill I, Tarone R, Vionnet JA, Grunberg S, Muggia FM, Reed E.
    Carcinogenesis; 1991 Jul 01; 12(7):1253-8. PubMed ID: 2070490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.